Published online Dec 18, 2023. doi: 10.13105/wjma.v11.i7.317
Peer-review started: May 18, 2023
First decision: July 28, 2023
Revised: August 23, 2023
Accepted: October 8, 2023
Article in press: October 8, 2023
Published online: December 18, 2023
Processing time: 210 Days and 3.7 Hours
Modern immunosuppression has led to a decrease in rejection rates and improved survival rates after solid organ transplantation. Increasing the potency of immunosuppression promotes post-transplant viral infections and associated cancers by impairing immune response against viruses and cancer immunoe
Core Tip: Post-transplant malignancy poses a serious threat with increased risk in organ recipients, varying with the intensity of net immunosuppression. Various virus infections are either causative or associative or promote the development of post-transplant malignancies. It is crucial to be aware of different viral infections so as to pre-emptively screen viral infections and survey for post-transplant cancers, helping early diagnosis, thereby favoring improved outcomes and graft survival. Transplant clinicians must be up to date on current management strategies with the vital role of immunosuppression reduction and options like antivirals, rituximab, chemotherapy, adoptive immunotherapy, topical therapy and surgery based on individual case characteristics.